Miguel Martín
Universidad Complutense de Madrid(ES)University College London Hospitals NHS Foundation Trust(GB)Simon Fraser University(CA)Hospital General Universitario Gregorio Marañón(ES)Centro de Investigación Biomédica en Red de Cáncer(ES)GEICAM – Spanish Breast Cancer Group(ES)Medical Research Network(US)University College London(GB)
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, Cancer Treatment and Pharmacology, HER2/EGFR in Cancer Research, Breast Cancer Treatment Studies, Cancer Genomics and Diagnostics
Most-Cited Works
- → Palbociclib and Letrozole in Advanced Breast Cancer(2016)2,879 cited
- → Adjuvant Trastuzumab in HER2-Positive Breast Cancer(2011)2,750 cited
- → Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials(2017)1,113 cited
- → Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3(2018)1,086 cited
- → Adjuvant Docetaxel for Node-Positive Breast Cancer(2005)951 cited
- → Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer(2019)821 cited